XBiotech Inc
Ownership
Ownership Structure
Who owns XBiotech Inc (XBIT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.4% of the shares are freely tradable; institutional investors hold 6.8%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 1.05 | 321,146 | +9.6 | 06/30/2026 |
| Geode Capital Management, LLC | 0.70 | 214,116 | -7.3 | 06/30/2026 |
| Vanguard Capital Management, LLC | 0.66 | 200,182 | -0.4 | 06/30/2026 |
| RBF LLC | 0.65 | 198,501 | +0.0 | 06/30/2026 |
| Morgan Stanley - Brokerage Accounts | 0.49 | 147,880 | -10.7 | 06/30/2026 |
| Bridgeway Capital Management, LLC | 0.32 | 98,447 | +0.0 | 06/30/2026 |
| Vanguard Fiduciary Trust Co | 0.30 | 92,365 | +0.9 | 06/30/2026 |
| Millennium Management LLC | 0.26 | 79,330 | -24.8 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Extended Market Index | 0.31 | 94,231 | -0.5 | 08/31/2026 |
| iShares Micro-Cap ETF | 0.25 | 74,972 | -0.7 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Simard John | Director | 4,191,690 | 7,964,211 $ | Oct 26, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Simard John | Director | Buy | 368,524 | 1.93 | 711,251 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.